Press "Enter" to skip to content

Accelerated Path to Cures | Josep Bassaganya-Riera | TEDxVirginiaTech


how many of us have rejected shun or

ignore medications just because the

treatment is worse than the disease how

many of us have taken

anti-inflammatories to come to the

realization that the side effects are as

warz as the disease symptoms

breakthroughs in precision medicine and

health going on at Virginia Tech are

about to change this trend Virginia Tech

has a unique opportunity to profoundly

change the drug development landscape in

the US and globally let the food be thy

medicine and medicine be thy food hi

pocket is the father of modern medicine

who is portrayed as the Paragon as the

ancient Greek physician had a clear

understanding of the connections between

food and medicine the medicinal value of

foods this concept is at the very core

of nutritional immunology research that

Virginia Tech is pioneering yet this

ancient principle of utilizing

nutritional foods as medicine is only

benefiting right now about 8% of the

u.s. population only about 8% of us are

for instance taking the five to nine

servings of fruits and vegetables that

are recommended the remaining ninety two

bio complexity this picture is at the

very core of bio complexity it

illustrates the interactions between

diet and foods where we have hundreds

maybe thousands of choices every day

trillions of bacteria in our intestines

and complex biochemical pathways that

drive

use of those nutrients in our intestines

which are intimately connected with an

immune system that can choose to be

when these systems get out of sync when

there’s a dysregulation at any of these

levels then disease follows and the God

the dysregulated God the God that is out

of balance has us running to the

hospital

I’ll talk now about Assad but a very

real example of stool Walker stew Walker

is a young man from West Yorkshire

England he wants to be normal he seems

healthy

however stew is not normal a store

requires feeding through a cube in his

nose a stool has a colostomy bag

connected to his abdomen and to his god

a store is one of four million people of

individuals worldwide afflicted by

inflammatory bowel disease an autoimmune

disease without a cure and with two

clinical manifestations Crohn’s disease

and ulcerative colitis current

treatments for IBD are modestly

successful in some cases 30 to 40

percent of patients benefit from those

treatments the side effects are severe

ranging from infection to cancer to

the cost of these medications is about

$50,000 per patient per year yes you

heard it right fifty thousand dollars

per patient per year and about seventy

percent of those patients will require

surgery in some cases several surgeries

in fact Stu has undergone several

surgeries to deal with his IBD this is a

symptom of a broader problem which is

illustrated by what we call the sideways

funnel of the drug development process

in the US there’s an inefficiency that

is embedded in the drug development

process from Discovery to preclinical

testing in animals to face one to three

clinical testing the process is

inefficient and slow-moving let’s look

at some facts and figures some food for

thought about developing a drug costs

about 1.2 billion dollars the timeline

for developing a drug for Crohn’s

disease is about 10 to 15 years and only

one in over 10,000 molecules are going

to make it there’s a cost efficiency

problem there’s an inefficiency problem

and you might ask what is our aim our

aim is to fold first to find a solution

for the needs of Stuart and the other 4

million people globally we need to find

safer and more effective medications for

IBD but second and equally importantly

to help address the inefficiency of the

drug development process let’s think

about it how can we accomplish that

engineers have over the years been using

effectively modeling and simulation the

power of high performance computing to

minimize

an error in building airplanes rocket

launchers even atomic bombs

the use of computational modeling

mechanistic modeling agent based

modeling in medicine is just beginning

to scratch the surface we believe that

there’s an opportunity in becoming the

engineers of the gut biochemical

biomedical researchers can become the

engineers of the guard the engineers of

the immune system we’ve come a long way

since hypotheses established his opinion

on the value of food as a medicinal

concept we’ve celebrated metchnikoff

as the discoverer of the macrophages one

of the immune cells monoclonal

antibodies have paved the way for

targeted research on a specific pathways

sequencing has improved performance up

to 10,000 fold over the last four to

five years and cost of sequencing have

steadily gone down computational

technologies have the potential to drive

the nave next revolution in biomedicine

research and in drug discovery we talked

about bio complexity the intestine is a

complex system one that we must

understand if we have to find people who

are able to find a cure for IBD we have

40 trillion bacteria 30 trillion cells

pro-inflammatory anti-inflammatory they

can be pro-inflammatory depending on the

environment or anti-inflammatory and

there’s plasticity that switches from a

pro to anti-inflammatory State believe

it or not 70 to 75 percent of the immune

system is present in our gut and the

surface area of our God is about the

size of two tennis courts

there’s trillions of interactions and we

must understand the God and the immune

system completely and in its entirety to

be able to make measure advances in the

development of cures for IBD the spark

here is the application of modeling and

simulation technologies the application

of the power of high-performance

computing to build models that will help

Stu and the other four million people

afflicted by IBD Virginia Tech is

leading the way on building

computational models of the stomach

during h pylori infection of the lower

intestine

during australium difficile infection

and yes we are also building models of

inflammatory bowel disease not only to

understand the basic fundamental

mechanisms that drive the immune system

to become dysregulated and destroy the

intestine but more importantly to

identify new cures for inflammatory

bowel disease even the youngest members

of this audience know how to solve the

equation of two plus two equals four not

all of us can solve the equation listed

in this slide well what this is telling

us that in order to make a meaningful

impact on drug discovery and on the

understanding of god immunology we need

to establish teams of mathematicians

computer scientists immunologist

formulation experts clinicians and

translational researchers and this

research is going on here

at Virginia Tech this is a clear example

of a destination for the University we

have utilized these modeling

technologies some of them similar to

what Google is utilizing on its engine

in its searches others that are ordinary

differential equations or agent-based

modeling to go from experimental

data to dissecting the whole organism

the tissue the cells and the molecules

and these analyses allow us to identify

new therapeutic targets one such example

of those promising therapeutic targets

is lanthanum synthetase you like to

discover here at Virginia Tech and a

promising Avenue to find a cure for

inflammatory bowel disease

Alan cl2 intercepts inflammatory bowel

disease at two levels first it

suppresses the pro inflammatory

mediators linked to IBD and next it

amplifies the anti inflammatory response

this technology is gaining momentum and

has been validated by the National

Institutes of Health the American

gastroenterology Association and the

Crohn’s and Colitis foundation of

America you don’t need to be a

board-certified pathologist to

understand that there’s a difference

between these two pictures on your left

we have an intestine from a mouse with

IBD the wall is thicker the architecture

is deranged there’s infiltration of

inflammatory cells on the right we have

an intestine of a mouse with IBD that

has been treated with a new drug that

targets lanthanum synthetase like to the

new drug is called BT 11 and what that

drug does is make those things on the of

the intestine be thinner less

inflammatory cell infiltration and

maintenance of the architecture we can

take modeling one step further we can

design the next generation of human

clinical trials we are using clinical

information from electronic health

records biological data demographic

information immunological datasets

to build avatars populations of patients

with inflammatory bowel disease

specifically Crohn’s disease where we

can test not only existing drugs but new

drugs I just beat the 11 and we have

accomplished that here those are the

results of comparing our new drug bt 11

which in mouse study showed efficacy at

8 milligrams per kilo and safety in

doses as high as 1000 milligrams per

kilo tested in human avatars and what

this data shows is that bt 11

outperforms current standard of care as

well as drugs in development we’ve come

a long way from hypothesis let food be

thy medicine let medicine be thy food –

modeling simulation and leveraging the

power of high-performance computing

we’ve built a product development

platform that is applicable to the

development of IBD drugs but has the

potential to be applied to other

diseases such as type 1 diabetes

rheumatoid arthritis multiple sclerosis

type 2 diabetes we have embarked on a

journey of a faster path to cures we

have embarked on a journey not only to

address the symptoms of the disease and

the discomfort caused by inflammatory

bowel disease but also to address the

inefficiency of the drug development

process by leveraging the power of

modeling and simulation and were honored

to be able to tell us to Walker his

family and his friends as well as the 4

million other people afflicted by IBD

that hope is on the way thank you very

much [Applause]

Please follow and like us: